Pfizer Pulls Back On European Viagra Switch As Questions Linger
This article was originally published in The Tan Sheet
Executive Summary
Pfizer withdraws its application to switch Viagra 50 mg from prescription to nonprescription status through the European Medicines Agency's centralized process, the company said Nov. 20
You may also be interested in...
With OTC Cialis Rights, Sanofi Launches Latest Salvo In Consumer Sector Battle
Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.
With OTC Cialis Rights, Sanofi Launches Latest Salvo In Consumer Sector Battle
Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.
OTC Oxytrol Approval In U.S. Highlights European Switch Struggles
Former McNeil Consumer Pharmaceuticals exec Stephen Mann says FDA’s approval of OTC Oxytrol poses a challenge to the EU, where Rx-to-OTC switches and the self-care movement face major obstacles. More regulators are weighing drug switches for chronic conditions, consultant Susan Coleman says.